Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380349 · ClinicalTrials.gov registry record · Early Phase 1
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
A Early Phase 1 study of Newly Diagnosed Glioblastoma, sponsored by Swedish Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05380349 is a Early Phase 1 study of Newly Diagnosed Glioblastoma that is actively recruiting participants, run by Swedish Medical Center. The registered enrollment target is 10 participants, below the 87-participant average among 4 other Newly Diagnosed Glioblastoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05380349, a Early Phase 1 study of Newly Diagnosed Glioblastoma, is actively recruiting participants, sponsored by Swedish Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
Conditions Studied
Interventions
- DRUG combinations of up to 3 FDA approved drugs from a panel of compounds
Study Locations (1)
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05380349
The ClinicalTrials.gov registry entry for NCT05380349 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 4 other Newly Diagnosed Glioblastoma trials with a reported enrollment target (89% lower). The listed sponsor is Swedish Medical Center, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Newly Diagnosed Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which combinations of up to 3 FDA approved drugs from a panel of compounds is the first listed.
NCT05380349 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT05380349 about?
NCT05380349 is a clinical study titled "Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma". Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
What is the current status of trial NCT05380349?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-04-19. Estimated completion is 2027-12.
What conditions does trial NCT05380349 study?
This clinical trial studies the following conditions: Newly Diagnosed Glioblastoma.
What interventions are being tested in trial NCT05380349?
The interventions under investigation include: combinations of up to 3 FDA approved drugs from a panel of compounds (DRUG).
Who is sponsoring clinical trial NCT05380349?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05380349 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Newly Diagnosed Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.